PROfound: A new hope for precise treatment of prostate cancer
10.12092/j.issn.1009-2501.2020.02.005
- VernacularTitle: PROfound研究-前列腺癌精准治疗新希望
- Author:
Houbao HUANG
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Wannan Medical College
- Publication Type:Journal Article
- Keywords:
Metastatic castrate-resistant prostate cancer;
Olaparib;
PROfound
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(2):144-150
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic castrate-resistant prostate cancer (mCRPC) is the last stage of prostate cancer. Although new hormonal agents and taxane-based chemotherapies occurred for mCRPC treatment, the overall survival of mCRPC patients is limited. Olaparib is an inhibitor of poly ADP-ribose polymerase (PARP), which has a key role in DNA damage response. It has been approved for ovarian cancer and breast cancer treatment. PROfound, a phase III clinical trial of olaparib in mCRPC treatment, has been reported in 2019 ESMO and 2020 ASCO-GU. In this paper, we will bring the results and updates of PROfound.
